Scholarlink

<p>Hypersensitivity pneumonitis (HP) presents with a highly variable clinical course, and traditional treatment includes systemic corticosteroids and strict antigen avoidance. The objective of this study was to evaluate the therapeutic potential of Rituximab in patients with progressive hypersensitivity pneumonitis who do not respond to antigen avoidance and conventional immunosuppressive therapy. In this cohort prospective study, 30 patients with refractory HP were enrolled. Forced Vital Capacity (FVC) was assessed at three time points: six months before Rituximab initiation (M − 6), at treatment initiation (M0), and six months later (M + 6). FVC% predicted significantly declined from (58.57 ± 10.9) at M − 6 to (51.03 ± 11.06%) at M0 [<i>p</i> &lt; 0.001], but showed a minimal, non-significant drop to 50.1 ± 12.7% at M + 6 [<i>p</i> = 0.405]. The rate of decline slowed markedly post-Rituximab, from − 7.54% (M − 6 to M0) to − 0.93% (M0 to M + 6). Dyspnea, measured by the mMRC scale, improved from 2.77 ± 0.5 at M0 to 1.83 ± 0.85 at M + 6 [<i>p</i> = 0.001]. 6MWD also increased from 258.67 ± 77&#xa0;m to 307 ± 99&#xa0;m [<i>p</i> = 0.001]. There were no reported cases of mortality. Rituximab demonstrates potential as an emerging therapeutic option for patients with treatment-refractory hypersensitivity pneumonitis and is well-tolerated.</p><p><i>Trial registration</i>: Retrospectively registered, registration number is NCT07035561, date of registration 16/06/2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rituximab therapy in patients with treatment-refractory hypersensitivity pneumonitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月17日

查看全文
  • Yosri Akl,
  • Safy Zahid Kaddah,
  • Shereen Medhat Nassar,
  • Rana Kamal EL Said

摘要

Hypersensitivity pneumonitis (HP) presents with a highly variable clinical course, and traditional treatment includes systemic corticosteroids and strict antigen avoidance. The objective of this study was to evaluate the therapeutic potential of Rituximab in patients with progressive hypersensitivity pneumonitis who do not respond to antigen avoidance and conventional immunosuppressive therapy. In this cohort prospective study, 30 patients with refractory HP were enrolled. Forced Vital Capacity (FVC) was assessed at three time points: six months before Rituximab initiation (M − 6), at treatment initiation (M0), and six months later (M + 6). FVC% predicted significantly declined from (58.57 ± 10.9) at M − 6 to (51.03 ± 11.06%) at M0 [p < 0.001], but showed a minimal, non-significant drop to 50.1 ± 12.7% at M + 6 [p = 0.405]. The rate of decline slowed markedly post-Rituximab, from − 7.54% (M − 6 to M0) to − 0.93% (M0 to M + 6). Dyspnea, measured by the mMRC scale, improved from 2.77 ± 0.5 at M0 to 1.83 ± 0.85 at M + 6 [p = 0.001]. 6MWD also increased from 258.67 ± 77 m to 307 ± 99 m [p = 0.001]. There were no reported cases of mortality. Rituximab demonstrates potential as an emerging therapeutic option for patients with treatment-refractory hypersensitivity pneumonitis and is well-tolerated.

Trial registration: Retrospectively registered, registration number is NCT07035561, date of registration 16/06/2025.